A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Malathion (Ovide)

Malathion slows cognitive decline in Alzheimer's disease by preserving acetylcholine levels.

First FDA approval2014-01-31
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$515,631 in CY2024 Part D spend3K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
$3.19/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.19
Across all dosage forms in distribution.
Highest NADAC
$3.19
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Malathion used for?

Malathion slows cognitive decline in Alzheimer's disease by preserving acetylcholine levels.

Is there a generic for Malathion?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Malathion?

Across 329 Part D plans, Malathion averages $3.19/unit (NADAC). Lowest available: $3.19/unit. Highest in distribution: $3.19/unit.

Is Malathion on the FDA shortage list?

No. Malathion is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Cholinesterase Inhibitor4 alternatives in D1
01
Donepezil
Brand: Aricept
$0.044Lowest NADAC
20Generic mfrs
$158.0MCY24 Part D spend
Compare →
02
Neostigmine Methylsulfate
Brand: Bloxiverz
Lowest NADAC
14Generic mfrs
CY24 Part D spend
Compare →
03
Pyridostigmine
Brand: Mestinon
$0.273Lowest NADAC
11Generic mfrs
$57.5MCY24 Part D spend
Compare →
04
Rivastigmine
Brand: Exelon
$0.150Lowest NADAC
13Generic mfrs
$145.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.